You may be surprised but more researches are saying this is possible. One vaccine so far, UB 311, has been getting a lot of attention. There is a Phase 2 trial evaluating UB 311’s ability to trigger an antibody response under way. The Phase 1 clinical trial included 19 patients with mild to moderate Alzheimer’s disease. The trial evaluated the vaccine’s immune response, safety and patients’ tolerance. UB 311 met all three goals, according to the results.